John D. Haley

6.1k total citations · 1 hit paper
95 papers, 4.8k citations indexed

About

John D. Haley is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John D. Haley has authored 95 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Molecular Biology, 33 papers in Oncology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John D. Haley's work include Lung Cancer Treatments and Mutations (14 papers), HER2/EGFR in Cancer Research (13 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). John D. Haley is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), HER2/EGFR in Cancer Research (13 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). John D. Haley collaborates with scholars based in United States, United Kingdom and Australia. John D. Haley's co-authors include Neil W. Gibson, Stuart Thomson, Filippo Petti, Kenneth K. Iwata, Elizabeth Buck, Graeme Griffin, Eric Brown, David Epstein, Hugh D. Niall and Alexandra Eyzaguirre and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

John D. Haley

89 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

2005 525 citations Stuart Thomson, Elizabeth Buck et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John D. Haley United States	34	2.8k	1.9k	1.1k	771	410	95	4.8k
Vessela S. Ivanova United States	9	4.3k 1.5×	1.3k 0.7×	460 0.4×	1.0k 1.4×	358 0.9×	15	5.4k
Anne W. Hamburger United States	29	2.7k 1.0×	2.2k 1.2×	555 0.5×	764 1.0×	178 0.4×	110	4.9k
Alfonso Calvo Spain	40	2.4k 0.9×	1.5k 0.8×	875 0.8×	1.0k 1.4×	98 0.2×	198	5.0k
Hideki Yokoyama Japan	31	2.9k 1.0×	1.1k 0.6×	1.3k 1.1×	406 0.5×	199 0.5×	85	5.2k
Bernard Salles France	43	4.5k 1.6×	2.0k 1.1×	334 0.3×	1.4k 1.9×	341 0.8×	134	6.0k
Massimo Derenzini Italy	44	4.2k 1.5×	1.1k 0.6×	440 0.4×	804 1.0×	416 1.0×	149	6.0k
Markus H. Frank United States	38	3.0k 1.1×	3.2k 1.7×	310 0.3×	1.0k 1.3×	808 2.0×	126	6.4k
Lee Goodglick United States	42	2.6k 0.9×	1.5k 0.8×	1.5k 1.3×	804 1.0×	70 0.2×	98	5.5k
Silvia Bruno Italy	32	2.9k 1.0×	1.1k 0.6×	350 0.3×	740 1.0×	138 0.3×	105	5.2k
Jason L. Parsons United Kingdom	37	3.3k 1.2×	2.2k 1.2×	550 0.5×	952 1.2×	161 0.4×	98	4.9k

Countries citing papers authored by John D. Haley

Since Specialization

Citations

This map shows the geographic impact of John D. Haley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Haley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Haley more than expected).

Fields of papers citing papers by John D. Haley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John D. Haley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Haley. The network helps show where John D. Haley may publish in the future.

Co-authorship network of co-authors of John D. Haley

This figure shows the co-authorship network connecting the top 25 collaborators of John D. Haley. A scholar is included among the top collaborators of John D. Haley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John D. Haley. John D. Haley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Wenxuan, Yao Fu, Chitra Thakur, et al.. (2025). Aryl Hydrocarbon Receptor (AHR) Suppresses Arsenic (As³⁺)-Induced Malignant Transformation by Antagonizing TOX Expression. International Journal of Biological Sciences. 21(6). 2747–2761.

Bronstein, Robert, et al.. (2024). Podocyte-specific KLF6 primes proximal tubule CaMK1D signaling to attenuate diabetic kidney disease. Nature Communications. 15(1). 8038–8038. 5 indexed citations

Haley, John D., et al.. (2024). Proteomic Analysis of Signaling Pathways Modulated by Fatty Acid Binding Protein 5 (FABP5) in Macrophages. Journal of Pharmacology and Experimental Therapeutics. 391(2). 289–300.

Coant, Nicolas, John D. Bickel, Ronald J. Rahaim, et al.. (2023). Neutral ceramidase-active site inhibitor chemotypes and binding modes. Bioorganic Chemistry. 139. 106747–106747. 1 indexed citations

Stith, Jeffrey L., et al.. (2023). Targeting sphingosine kinase 1 in p53KO thymic lymphoma. The FASEB Journal. 37(11). e23247–e23247. 1 indexed citations

Hwang, Ga‐Ram, et al.. (2023). Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer. Molecular Therapy — Oncolytics. 28. 277–292. 5 indexed citations

Wang, Nan, et al.. (2021). Impact of Target Turnover on the Translation of Drug-Target Residence Time to Time-Dependent Antibacterial Activity. ACS Infectious Diseases. 7(9). 2755–2763. 8 indexed citations

Min, Kyunghun, et al.. (2021). Integrative multi-omics profiling reveals cAMP-independent mechanisms regulating hyphal morphogenesis in Candida albicans. PLoS Pathogens. 17(8). e1009861–e1009861. 14 indexed citations

Ruiz, Christian, et al.. (2019). Decoupling of Nrf2 Expression Promotes Mesenchymal State Maintenance in Non-Small Cell Lung Cancer. Cancers. 11(10). 1488–1488. 6 indexed citations

10.

Wang, Jingming, Bryan Chan, Michael Tong, et al.. (2019). Prolyl isomerization of FAAP20 catalyzed by PIN1 regulates the Fanconi anemia pathway. PLoS Genetics. 15(2). e1007983–e1007983. 10 indexed citations

11.

Ullman, Erica, et al.. (2014). Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models. Frontiers in Oncology. 4. 344–344. 16 indexed citations

12.

Thomson, Stuart, et al.. (2008). Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clinical & Experimental Metastasis. 25(8). 843–854. 156 indexed citations

13.

Buck, Elizabeth, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, et al.. (2008). Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors. Cancer Research. 68(20). 8322–8332. 164 indexed citations

14.

Barr, Sharon, Suzanne Russo, Elizabeth Buck, et al.. (2007). The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells. Molecular Cancer Therapeutics. 6. 3 indexed citations

15.

Buck, Elizabeth, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, et al.. (2007). Inhibition of IGF-1R by OSI-906 potentiates efficacy of various molecular targeted agents by blocking feedback loops converging at the level of IRS-1. Molecular Cancer Therapeutics. 6. 1 indexed citations

16.

Buck, Elizabeth, Alexandra Eyzaguirre, Stuart Thomson, et al.. (2007). Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascade. Molecular Cancer Therapeutics. 6. 1 indexed citations

17.

Booth, D., John D. Haley, Arthur M. Bruskin, & Christopher S. Potten. (2000). Transforming growth factor-?3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem-cell cycling. International Journal of Cancer. 86(1). 53–59. 65 indexed citations

18.

Stewart, Alexander A., John D. Haley, Kees Stam, et al.. (1996). Umbilical Cord Transforming Growth Factor-β3: Isolation, Comparison with Recombinant TGF-β3 and Cellular Localization. Growth Factors. 13(1-2). 87–98. 11 indexed citations

19.

Haley, John D., et al.. (1989). ANALYSIS OF MAMMALIAN FIBROBLAST TRANSFORMATION BY NORMAL AND MUTATED HUMAN EGF RECEPTORS. UCL Discovery (University College London). 26 indexed citations

20.

Haley, John D., Peter J. Hudson, Denis B. Scanlon, et al.. (1982). Porcine Relaxin: Molecular Cloning and cDNA Structure. DNA. 1(2). 155–162. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact